Dana-Farber Cancer Institute unveils groundbreaking blood test for multiple myeloma
Advertisement
Researchers at Dana-Farber Cancer Institute have developed a blood test that could transform the diagnosis and monitoring of multiple myeloma (MM) and its precursor conditions. The new method, known as SWIFT-seq, utilizes single-cell sequencing to profile circulating tumor cells (CTCs) in the blood, offering a non-invasive alternative to traditional bone marrow biopsies. The study was published in Nature Cancer.
“A lot of work has gone into the identification of genomic and transcriptomic features that predict worse outcome in MM, but we are still lacking the tests to measure them in our patients, said senior author, Dr. Irene M. Ghobrial. “As a clinician, this is the type of next-generation test that I would want to order for my patients.”
Multiple myeloma is a challenging bone marrow cancer, often preceded by conditions such as Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM). Traditionally, bone marrow biopsies have been used to assess risk and monitor genetic changes in these conditions. However, these biopsies are painful, infrequent, and the accompanying technique, Fluorescence in situ hybridization (FISH), often fails to provide clear results, leading to less effective risk assessment and influencing treatment decisions.
“It would be amazing if we had a blood-based test that can outperform FISH and that works in the majority of patients – we think SWIFT-seq may just be that test,” said Dr. Romanos Sklavenitis-Pistofidis, co-first author.
SWIFT-seq offers an innovative alternative by allowing doctors to perform risk assessments and genetic monitoring using a simple blood test, making the process much easier and more reliable. Beyond counting CTCs, SWIFT-seq provides a detailed genetic profile, identifying key genetic changes crucial for understanding the disease. This method surpasses the accuracy of bone marrow tests like FISH. Additionally, SWIFT-seq evaluates tumor growth rates and identifies important gene patterns that can predict patient outcomes, all from a single blood sample.
“SWIFT-seq is a powerful option as it can measure the number of CTCs, characterize the genomic alterations of the tumor, estimate the tumor’s proliferative capacity and measure prognostically useful gene signatures in a single test and from a blood sample,” said Ghobrial.
The study involved 101 patients and healthy donors, demonstrating that SWIFT-seq successfully captured CTCs in 90% of patients with MGUS, SMM, and MM. Notably, it identified CTCs in 95% of patients with SMM and 94% of patients with newly diagnosed MM, the groups most likely to benefit from improved risk stratification and genomic surveillance. SWIFT-seq's ability to enumerate CTCs based on the tumor's molecular barcode, rather than relying on cell surface markers, sets it apart from existing methods like flow cytometry.
SWIFT-seq not only measures multiple clinically relevant features directly from a blood sample but also provides novel insights into the biology of tumor cell circulation.
“We identified a gene signature that we believe captures the tumor’s circulatory capacity and may partly explain some of the unexplained mysteries of myeloma biology,” said Dr. Elizabeth D. Lightbody, co-first author. “This can have a tremendous impact in how we think about curtailing tumor spread in patients with myeloma and could lead to the development of new drugs for patients.”
The introduction of SWIFT-seq marks a significant advancement in myeloma diagnostics, offering a minimally invasive method to obtain multiple layers of clinically useful information from a single blood test. This breakthrough could lead to improved patient outcomes and a deeper understanding of myeloma biology.
Other news from the department science
Most read news
More news from our other portals
Last viewed contents
Milestone for medical research: New method enables comprehensive identification of omega fatty acids - Researchers at the University of Graz and the University of California, San Diego present an effective method to determine omega positions of lipids in complex biological samples including human tissues and blood
Humify – superfood for the soil - Fighting climate change with green chemistry: The start-up Humify has developed a technology that can reactivate soil as a carbon sink
BINDER acquires Parameter Generation & Control
Sanofi to acquire biotech start-up Vicebio - Expanding respiratory vaccines pipeline
Where science powers start-ups - New biotech hub BioLabs|TUM launched to foster start-ups
Labguru and Titian Software Rebrand as Cenevo - Cenevo brings together lab management systems Labguru and Mosaic to unlock the full potential of labs and accelerate scientific discovery
€12M for LIfT BioSciences: Breakthrough in Cancer Therapy? - The grant from Ireland's Disruptive Technologies Innovation Fund will support the first-in-human clinical trial of LIfT's IMAN therapy
Bayer posts positive second quarter and progress on strategic priorities
Merck Delivers Profitable Organic Growth Amid Strong Currency Headwinds - Strong sales in Process Solutions and for blockbusters Mavenclad and Erbitux, sustained demand for Semiconductor Materials
Head-to-head against AI, pharmacy students won - A study showed that when compared with students, ChatGPT 3.5 was less likely to correctly answer questions on therapeutics exams focused on clinical applications and cases.
How immune cells switch into attack mode - New insights into macrophage biology
